Clinical Trials Browser

Phase 2 × OTHER × ARQ 197 × Clear all

NCT02608411 2023-10-13

TIMES

Phase 2 Terminated

Carcinoma, Small Cell

NCT01892527 2022-09-09

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Phase 2 Completed

Gastrointestinal

Colorectal Cancer Metastatic